CME: Tensynovial Giant Cell Tumor (TGCT): New Perspectives on Advances in Treatment

Tenosynovial Giant Cell Tumor (TGCT): New Perspectives on Advances in Treatment

Tenosynovial Giant Cell Tumor (TGCT): New Perspectives on Advances in Treatment
RestartResume
Patients with tenosynovial giant cell tumors can be managed with surgery, but it’s not a cure. And what happens when surgery is no longer an option?

Available credits: 0.25

Time to complete: 15 Minutes

Released:

Valid until:

Take Post-Test

If you’ve already completed the activity.

  • Overview

    To understand recent advances in the medical management of tenosynovial giant cell tumors (TGCT), join our expert faculty for a discussion on approaches you can take to achieve tumor size reduction and improvements in physical function, pain, and quality of life for your patients with TGCT.

  • Disclosure of Conflicts of Interest

    In accordance with the ACCME Standards for Commercial Support, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. GLC resolves all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.

    Host:
    William D. Tap, MD
    Chief, Sarcoma Medical Oncology Service
    Memorial Sloan Kettering Cancer Center
    New York, NY

    Leadership: Atropos Pharmaceuticals, Certis Oncology Solutions

    Ownership Interests: Atropo, Certis Oncology Solutions

    Consulting Fees: Agios, Blueprint Medicines, Daiichi Sankyo, Eisai, EMD Serono, GlaxoSmithKline, Immune Design, Janssen, Lilly, Loxo, Nanocel, Novartis, Plexxikon

    Contracted Research: BioAtla, Blueprint Medicines, Daiichi Sankyo, Decipher, Immune Design, Lilly, Novartis, Plexxikon, TRACON Pharma

    Patents, Royalties, Other Intellectual Property: Companion Diagnostic for CDK4 inhibitors, Methods of Treating Metastatic Sarcoma Using Talimogene Laherparepvec (T-Vec) and Pembrolizumab Combination Therapy

    Faculty:
    Silvia Stacchiotti, MD
    Medical Oncologist
    Adult Mesenchymal and Rare Tumor Medical Treatment Unit
    Cancer Medicine Department
    Fondazione IRCCS Instituto Nazionale Tumori
    Milan, Italy

    Advisory Board: Adaptimmune, Bayer, Daiichi Sankyo, Deciphera, Eli Lilly, Epizyme, lmmunedesign, Karyopharm, Maxivax, PharmaMar
    Consulting Fees: Bavarian
    Honoraria: Eli Lilly, PharmaMar, Takeda
    Contracted Research (Institutional financial interests): Advenchen, Amgen, Bayer, Blueprint, Daiichi Sankyo, Epizyme, Karyopharm, Lilly, Novartis, PharmaMar, Pfizer

    Michiel van de Sande, MD, PhD
    Orthopedic Surgeon
    Leiden University Medical Center
    Leiden, The Netherlands
    Dr. van de Sande has no relationship reported.

    Andrew J. Wagner, MD, PhD
    Medical Director, Adult Ambulatory Oncology
    Associate Chief Medical Officer
    Center for Sarcoma and Bone Oncology
    Dana-Farber Cancer Institute
    Boston, Massachusetts

    Honoraria: Novartis

    Consulting Fees: Daiichi Sankyo, Five Prime Therapeutics, Lilly, Loxo

    Contracted Research: AADi, Celldex, Daiichi Sankyo, Karyopharm Therapeutics, Lilly, Plexxikon

    Reviewers/Content Planners/Authors:

    • Rob Braun has nothing to disclose.
    • Ann Early has nothing to disclose.
    • Jessica McGrory has nothing to disclose.
    • William A. Mencia, MD has nothing to disclose.

     

  • Learning Objectives

    The goal of this activity is to enable effective collaboration and communication between the members of the professional teams who care for patients with Tenosynovial Giant Cell Tumor (TGCT).  After participating in this educational activity, participants should be better able to:

    • Describe the correlation between TGCT pathophysiology and the efficacy of emerging treatments in managing the disease
    • Formulate treatment strategies that include pharmacologic alternatives in patients with TGCT who may not benefit from surgery
    • Identify potential strategies for monitoring and managing adverse events related with emerging pharmacologic therapies
  • Target Audience

    This activity is designed to meet the educational needs of oncologists, surgical oncologists, orthopedic surgeons; oncology and orthopedic nurses, nurse practitioners, and physician assistants; and rheumatologists, rheumatology nurse practitioners, physician assistants; and other members of the interprofessional team who are involved in the management of patients with TGCT.

  • Accreditation and Credit Designation Statements

    Global Learning Collaborative is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    Global Learning Collaborative designates this enduring material for a maximum of .25 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

  • Provider(s)/Educational Partner(s)

    Prova Education, designs and executes continuing education founded on evidence-based medicine, clinical need, gap analysis, learner feedback, and more. Our mission is to serve as an inventive and relevant resource for clinical content and educational interventions across a broad spectrum of specialties. 

    Prova Education's methodology demonstrates a commitment to continuing medical education and the innovative assessment of its effects. Our goal is clear—to develop and deliver the very best education in the most impactful manner and to verify its results with progressive outcomes research. 

  • Commercial Support

    This activity is supported by an independent educational grant from Daiichi Sankyo.

  • Disclaimer

    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and Prova Education. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to link to a site outside of Prova Education you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.

    Reproduction Prohibited

    Reproduction of this material is not permitted without written permission from the copyright owner.

  • System Requirements

    Our site requires a computer, tablet or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/cable). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Internet Explorer, Microsoft Edge, Chrome, Firefox or Safari. Users accustomed to IE8, IE9 IE10 are advised to update their browsers for the best experience.

Facebook Comments

Sign up for the Global Oncology Academy newsletters.
Comprehensive Oncology Education.

Better education for a better you.

* Required
Optional

NEW FEATURES:

Register

We’re glad to see you’re enjoying Global Oncology Academy…
but how about a more personalized experience?

Register for free